Published in PLoS One on June 28, 2016
Vemurafenib and trametinib reduce expression of CTGF and IL-8 in (V600E)BRAF melanoma cells. Lab Invest (2017) 0.80
Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro. PLoS One (2017) 0.75
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Cancer immunotherapy comes of age. Nature (2011) 12.35
WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer (2013) 6.64
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature (2015) 3.86
Diversity of LEF/TCF action in development and disease. Oncogene (2006) 2.84
Control of neural crest cell fate by the Wnt signalling pathway. Nature (1998) 2.71
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol (2013) 2.64
Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A (2009) 2.41
Loss of beta-catenin expression associated with disease progression in malignant melanoma. Br J Dermatol (2001) 2.00
Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/β-catenin signaling and decreased Mitf levels. J Invest Dermatol (2011) 1.97
MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells. Proc Natl Acad Sci U S A (2015) 1.68
The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res (2009) 1.64
Expression of Dickkopf genes is strongly reduced in malignant melanoma. Oncogene (2006) 1.53
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
In melanoma, beta-catenin is a suppressor of invasion. Oncogene (2011) 1.40
β-Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance. PLoS One (2011) 1.25
Beta-catenin inhibits melanocyte migration but induces melanoma metastasis. Oncogene (2012) 1.18
Curcumin inhibits connective tissue growth factor gene expression in activated hepatic stellate cells in vitro by blocking NF-kappaB and ERK signalling. Br J Pharmacol (2007) 1.13
CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration. Br J Cancer (2011) 1.12
Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. Pigment Cell Melanoma Res (2015) 1.12
Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med (1999) 1.06
Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. Pigment Cell Melanoma Res (2011) 1.04
Antiproliferative and antiproteolytic activity of pentoxifylline in cultures of B16F10 melanoma cells. Cancer Chemother Pharmacol (2005) 1.00
CTGF is a therapeutic target for metastatic melanoma. Oncogene (2013) 1.00
Reduced CTGF expression promotes cell growth, migration, and invasion in nasopharyngeal carcinoma. PLoS One (2013) 0.99
Acquired and intrinsic resistance in cancer immunotherapy. Mol Oncol (2014) 0.98
MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci (2014) 0.97
Downregulation of connective tissue growth factor by three-dimensional matrix enhances ovarian carcinoma cell invasion. Int J Cancer (2009) 0.95
Activation of Wnt/β-catenin signaling increases apoptosis in melanoma cells treated with trail. PLoS One (2013) 0.95
ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. Cancer Res (2014) 0.94
Sphere formation and self-renewal capacity of melanoma cells is affected by the microenvironment. Melanoma Res (2012) 0.92
Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma. Oncogene (2014) 0.91
Pro-survival role of MITF in melanoma. J Invest Dermatol (2014) 0.91
Inhibition by pentoxifylline of TNF-alpha-stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF-kappa B down-regulation. Br J Pharmacol (2003) 0.89
Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres. Cancer Biol Ther (2012) 0.89
The role of G2-block abrogation, DNA double-strand break repair and apoptosis in the radiosensitization of melanoma and squamous cell carcinoma cell lines by pentoxifylline. Int J Radiat Biol (2000) 0.86
Natural compounds' activity against cancer stem-like or fast-cycling melanoma cells. PLoS One (2014) 0.86
Parthenolide enhances dacarbazine activity against melanoma cells. Anticancer Drugs (2013) 0.84
Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype. PLoS One (2014) 0.84
Phenotypic diversity of patient-derived melanoma populations in stem cell medium. Lab Invest (2015) 0.84
Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling. PLoS One (2014) 0.84
Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells. Br J Pharmacol (2010) 0.83
Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity. PLoS One (2014) 0.83
Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Cancer Biol Ther (2015) 0.82
Cancer stem cells, pluripotency, and cellular heterogeneity: a WNTer perspective. Curr Top Dev Biol (2014) 0.82
Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-Mhigh melanoma cell populations. Oncotarget (2016) 0.81
Pentoxifylline inhibits melanoma tumor growth and angiogenesis by targeting STAT3 signaling pathway. Biomed Pharmacother (2013) 0.81
Multiplying therapies and reducing toxicity in metastatic melanoma. Cancer Biol Ther (2015) 0.79
Preclinical evaluation of the antimetastatic efficacy of Pentoxifylline on A375 human melanoma cell line. Biomed Pharmacother (2012) 0.79
Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3. PLoS One (2015) 0.79
Pentoxifylline augments TRAIL/Apo2L mediated apoptosis in cutaneous T cell lymphoma (HuT-78 and MyLa) by modulating the expression of antiapoptotic proteins and death receptors. Biochem Pharmacol (2010) 0.78
Pentoxifylline triggers autophagy via ER stress response that interferes with Pentoxifylline induced apoptosis in human melanoma cells. Biochem Pharmacol (2016) 0.78
Targeted Therapies in Melanoma: Translational Research at Its Finest. J Invest Dermatol (2015) 0.78
Potentiation of antimetastatic activity of pentoxifylline in B16F10 and B16F1 melanoma cells through inhibition of glutathione content. Cancer Biother Radiopharm (2003) 0.77
Reply: Regulatory T cells-an important target for cancer immunotherapy. Nat Rev Clin Oncol (2014) 0.77
When are signal transduction targeted therapies acting as immunotherapy? Cancer Biol Ther (2015) 0.76
Melanoma immunotherapy. Cancer Biol Ther (2014) 0.76
Pro-survival role of MITF in melanoma. J Invest Dermatol (2014) 0.91
Natural compounds' activity against cancer stem-like or fast-cycling melanoma cells. PLoS One (2014) 0.86
Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype. PLoS One (2014) 0.84
Phenotypic diversity of patient-derived melanoma populations in stem cell medium. Lab Invest (2015) 0.84
Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-Mhigh melanoma cell populations. Oncotarget (2016) 0.81
Vemurafenib and trametinib reduce expression of CTGF and IL-8 in (V600E)BRAF melanoma cells. Lab Invest (2017) 0.80
MCL-1, BCL-XL and MITF Are Diversely Employed in Adaptive Response of Melanoma Cells to Changes in Microenvironment. PLoS One (2015) 0.79
Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro. PLoS One (2017) 0.75
Expression of miRNAs as Important Element of Melanoma Cell Plasticity in Response to Microenvironmental Stimuli. Anticancer Res (2015) 0.75